Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines)

• US 8,980,265 B2
• Filed: 03/14/2003
• Issued: 03/17/2015
• Est. Priority Date: 09/15/2000
• Status: Active Grant

• Current Assignee: Biontech AG
• Original Assignee: Biontech AG
• Inventors: Pfizenmaier, Klaus, Wajant, Harald, Moosmayer, Dieter, Wuest, Thomas
• Primary Examiner(s): Shukla, Ram R
• Assistant Examiner(s): HOLLERAN, ANNE L
• Application Number:
  US10/389,223
• Publication Number:
  US 20040033511A1
• Time in Patent Office: 4,386 Days
• Field of Search: 530/387.1, 530/387.3, 530/388.1, 530/388.22, 530/388.75, 530/391.1, 530/391.3, 530/391.5, 530/391.7, 530/391.9, 424/130.1, 424/133.1, 424/134.1, 424/135.1, 424/141.1, 424/143.1, 424/154.1, 424/85.1
• US Class Current: 424/134.1
• CPC Class Codes: A61K 47/6899 Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C07K 14/525 Tumour necrosis factor [TNF]
• CPC Class Codes: C07K 14/70575 NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 NGF C07K14/48, TNF C07K14/525
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumor tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimized for the respective indication/tumor entity.

Claims

1. A polypeptide comprising:

(i) a segment (1) that is FasL extracellular domain consisting of the amino acid sequence of SEQ ID NO;

14;

(ii) a segment (2) comprising a non-multimerizing peptide linker that is linked to the N-terminus of segment (1), wherein the amino acid sequence of the linker consists of the sequence selected from the group consisting of AAAVELE (SEQ ID NO;

     21), RTVAAPSVFAVFAAAVELE (SEQ ID NO;

     20) and RTVAAPSVFAVFAAA (SEQ ID NO;

     22); and

(iii) a segment (3) comprising a single chain antibody that selectively recognizes a specific fibroblast activation protein (FAP) target molecule on a cell surface, said segment (3) being linked to the N-terminus of segment (2),

wherein the FasL extracellular domain causes formation of a trimer, wherein a trimer of the FasL extracellular domain alone has no or limited biological activity, wherein the biological activity of the FasL extracellular domain trimer is activated upon binding of the segment (3) portion of the polypeptide to the target FAP molecule on the cell surface, and wherein the biological activity comprises the ability to induce apoptosis.

2. A composition comprising a polypeptide according to claim 1, and a pharmaceutically acceptable excipient, additive and/or carrier.

3. A polypeptide comprising:

(i) a segment (1) consisting of the FasL extracellular domain;

(ii) a segment (2) comprising a non-multimerizing peptide linker that is linked to the N-terminus of segment (1), wherein the amino acid sequence of the linker consists of the sequence selected from the group consisting of AAAVELE (SEQ ID NO;

     21), RTVAAPSVFAVFAAAVELE (SEQ ID NO;

     20) and RTVAAPSVFAVFAAA (SEQ ID NO;

     22); and

(iii) a segment (3) comprising a single chain antibody that selectively recognizes a target molecule on a cell surface, said segment (3) being linked to the N-terminus of segment (2),

wherein the FasL extracellular domain causes formation of a trimer, wherein a trimer of the FasL extracellular domain alone has no or limited biological activity, wherein the biological activity of the FasL extracellular domain trimer is activated upon binding of the segment (3) portion of the polypeptide to the target molecule on the cell surface, and wherein the biological activity comprises the ability to induce apoptosis.